"Robust December" helps Danaher's Q4 beat analyst expectations
This article was originally published in Clinica
Executive Summary
Danaher is expecting to report organic revenue growth of over 3% in its fourth fiscal quarter, above the 1% increase anticipated by Jefferies analyst Jon Wood and consensus analyst estimates. The results, aided by what the analyst described as a "robust December showing", should push Q4 earnings-per-share above the company's previous guidance of $0.80-0.85.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.